Q4 2017 EPS Estimates for PRA Health Sciences, Inc. (PRAH) Lifted by Jefferies Group

PRA Health Sciences, Inc. (NASDAQ:PRAH) – Analysts at Jefferies Group boosted their Q4 2017 earnings per share estimates for PRA Health Sciences in a research note issued to investors on Monday. Jefferies Group analyst D. Windley now forecasts that the medical research company will post earnings per share of $0.91 for the quarter, up from their prior estimate of $0.89. Jefferies Group has a “Buy” rating and a $92.00 price objective on the stock.

A number of other research analysts have also weighed in on the stock. Robert W. Baird reissued a “buy” rating and set a $88.00 target price on shares of PRA Health Sciences in a research report on Monday. Mizuho assumed coverage on shares of PRA Health Sciences in a research report on Thursday, September 21st. They set a “buy” rating and a $82.00 target price for the company. Zacks Investment Research raised shares of PRA Health Sciences from a “hold” rating to a “buy” rating and set a $83.00 target price for the company in a research report on Tuesday, September 19th. Finally, Raymond James Financial, Inc. assumed coverage on shares of PRA Health Sciences in a research report on Wednesday, August 16th. They set an “outperform” rating and a $89.00 target price for the company. One analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $84.78.

WARNING: This news story was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this news story on another site, it was illegally copied and reposted in violation of US & international copyright and trademark law. The correct version of this news story can be accessed at https://sportsperspectives.com/2017/10/12/q4-2017-eps-estimates-for-pra-health-sciences-inc-prah-lifted-by-jefferies-group.html.

Shares of PRA Health Sciences (PRAH) traded up 0.13% during mid-day trading on Wednesday, hitting $81.79. The stock had a trading volume of 49,444 shares. The company has a market cap of $5.12 billion, a PE ratio of 52.80 and a beta of 0.42. The firm’s 50 day moving average price is $76.81 and its 200-day moving average price is $72.58. PRA Health Sciences has a one year low of $50.87 and a one year high of $82.00.

PRA Health Sciences (NASDAQ:PRAH) last announced its earnings results on Monday, August 7th. The medical research company reported $0.62 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.72 by ($0.10). PRA Health Sciences had a return on equity of 21.17% and a net margin of 5.15%. The business had revenue of $457.90 million for the quarter, compared to analysts’ expectations of $447.79 million. During the same period in the previous year, the firm posted $0.63 earnings per share. The firm’s revenue was up .5% compared to the same quarter last year.

Institutional investors and hedge funds have recently made changes to their positions in the company. PNC Financial Services Group Inc. raised its position in shares of PRA Health Sciences by 175.7% during the first quarter. PNC Financial Services Group Inc. now owns 44,764 shares of the medical research company’s stock valued at $2,921,000 after buying an additional 28,526 shares during the last quarter. State Board of Administration of Florida Retirement System raised its position in shares of PRA Health Sciences by 32.3% during the second quarter. State Board of Administration of Florida Retirement System now owns 28,968 shares of the medical research company’s stock valued at $2,173,000 after buying an additional 7,076 shares during the last quarter. Renaissance Group LLC raised its position in shares of PRA Health Sciences by 2.5% during the second quarter. Renaissance Group LLC now owns 5,239 shares of the medical research company’s stock valued at $393,000 after buying an additional 126 shares during the last quarter. Sheaff Brock Investment Advisors LLC acquired a new position in shares of PRA Health Sciences during the second quarter valued at about $1,016,000. Finally, Seven Eight Capital LP acquired a new position in shares of PRA Health Sciences during the second quarter valued at about $840,000. 98.37% of the stock is owned by institutional investors and hedge funds.

In other news, major shareholder Pra Investors L.P. Kkr sold 9,500,000 shares of the company’s stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $74.85, for a total transaction of $711,075,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Colin Shannon sold 400,000 shares of the company’s stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $74.85, for a total transaction of $29,940,000.00. The disclosure for this sale can be found here. Insiders have sold 10,000,000 shares of company stock valued at $748,500,000 in the last ninety days. 2.10% of the stock is owned by company insiders.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Earnings History and Estimates for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply